Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| HALO | IEI | |
|---|---|---|
Market Cap | $12.58B | $16.72B |
Volume | 2,179,278 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $115.22 | $120.72 |
52-Week Low | $61.63 | $113.17 |
Typical Hold Time | 1 Days | 43 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.
Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
